A Comparative Study of Myoinositol and Metformin for Ovulation Induction in Pregnant Women with PCOS

Abstract

Introduction: PCOS is a common condition in women of reproductive age characterized by ovulatory dysfunction, androgen excess and polycystic ovaries. Myoinositol and metformin have both been studied as potential treatment options for inducing ovulation in women with PCOS. Aim of the Study: The aim of the study was to compare the use of myoinositol and metformin for ovulation induction in pregnant women with PCOS. Methods: This comparative observational cross-sectional study was conducted at the Manikganj 250 Bedded Sadar hospital, Dhaka, Bangladesh from January 2022 to December 2022. A total of 100 patients with PCOS were selected for this study. The participants were divided into 2 equal groups of 50 patients each, where patients in the first group were treated with myoinositol, and patients in the second group were treated with metformin. Result: In our study, there was a decrease in mean weight, BMI, and waist-hip ratio of both groups after treatment but with no statistically significant (p>0.05) difference between the groups. There was an improvement in menstrual cycle in both groups after treatment with no statistically significant (p>0.05) difference between the groups. The LH/FSH ratio decreased more in the myoinositol group after treatment compared to the metformin group but there was no statistically significant (p>0.05) difference between the groups. Fasting Insulin decreased similarly in both groups but there was no statistically significant (p>0.05) difference between the groups. HOMA-IR decreased in both groups with a statistically significant (p<0.05) difference after treatment. We found that myo-inositol administration in PCOS subjects led to statistically significant (p<0.05) decreases in FAI compared to the metformin group. Ovarian volume decreased from 12.59±5.15 cm3 to 10.05±4.50 cm3 in the myoinositol group and 12.90±5.62 cm3 to 10.65±4.10 cm3 in metformin group. The groups had no statistically significant (p>0.05) difference. The conception ....